prescription glp 1 GLP-1 Semaglutide Rx and stomach upset GLP-1 Prescribing Is Rising —

A well-designed oral product can improve access, support wider commercial reach and give more flexibility across healthcare settings

Blue Cross said it spent $515 million on GLP-1s in 2025, up from $140 million in 2023

Strategic Implications/Executive Takeaways Focus on Multi-Condition Solutions: As GLP-1 receptor agonists gain traction in treating both type 2 diabetes and obesity, companies should emphasize these dual benefits to capture a broader patient base

In the meantime, the availability of the two highest-dose Zepbound vials gives providers and patients another important treatment option."(Source: Eli Lilly & Co., June 2025) Ozempic captures close to 60% of the GLP-1 receptor agonist category, underscoring its lead among semaglutide-based therapies

We offer: Financial Impact Analysis : Forecasting cost impacts and developing mitigation strategies